Journal article
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
The New England journal of medicine, Vol.385(8), pp.683-694
08/19/2021
DOI: 10.1056/NEJMoa2106391
PMID: 34895924
Abstract
In a double-blind, randomized trial involving nearly 1000 patients followed for a median of 2 years, pembrolizumab injections for 1 year after surgery led to improved disease-free survival at 24 months as compared with placebo (77% vs. 68%). Almost one third of patients in the pembrolizumab group had a grade 3 adverse event, but no deaths were due to pembrolizumab.
Details
- Title: Subtitle
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Creators
- Toni K Choueiri - Dana-Farber Cancer InstitutePiotr Tomczak - Poznan University of Medical SciencesSe Hoon Park - Samsung Medical CenterBalaji Venugopal - University of GlasgowThomas Ferguson - Fiona Stanley HospitalYen-Hwa ChangJaroslav Hajek - University Hospital OstravaStefan N Symeonides - Edinburgh Cancer ResearchJae Lyun LeeNaveed Sarwar - Imperial College Healthcare NHS TrustAntoine Thiery-VuilleminMarine Gross-GoupilMauricio Mahave - Fundación Arturo López PérezNaomi B Haas - Sidney Kimmel Cancer CenterPiotr Sawrycki - Provincial Polyclinical Hospital in ToruńHoward Gurney - Macquarie UniversityChristine ChevreauBohuslav MelicharEvgeniy KopyltsovAjjai Alva - University of MichiganJohn M Burke - Rocky Mountain Cancer CentersGurjyot DoshiDelphine TopartStephane OudardHans Hammers - The University of Texas Southwestern Medical CenterHiroshi KitamuraJens BedkeRodolfo F Perini - Merck & Co., Inc., Rahway, NJ, USAPingye Zhang - Merck & Co., Inc., Rahway, NJ, USAKentaro Imai - Merck & Co., Inc., Rahway, NJ, USAJaqueline Willemann-Rogerio - Merck & Co., Inc., Rahway, NJ, USADavid I Quinn - University of Southern CaliforniaYousef Zakharia - University of Iowa, Hematology, Oncology, and Blood & Marrow TransplantationThomas Powles - University College London
- Contributors
- KEYNOTE-564 Investigators (Contributor)Yousef Zakharia (Contributor) - University of Iowa, Hematology, Oncology, and Blood & Marrow Transplantation
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.385(8), pp.683-694
- DOI
- 10.1056/NEJMoa2106391
- PMID
- 34895924
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Grant note
- Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.
- Language
- English
- Date published
- 08/19/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984546644602771
Metrics
18 Record Views